Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice

Wetterauer, Christian; Vlajnic, Tatjana; Schüler, Julia; Gsponer, Joel R; Thalmann, George; Cecchini, Marco Giovanni; Schneider, Julia; Zellweger, Tobias; Püschel, Heike; Bachmann, Alexander; Ruiz, Christian; Dirnhofer, Stephan; Bubendorf, Lukas; Rentsch, Cyrill Achim (2015). Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice. Prostate, 75(6), pp. 585-592. Wiley-Blackwell 10.1002/pros.22939

[img] Text
pros22939.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

BACKGROUND There is an urgent need for preclinical models of prostate cancer; however, clinically relevant patient-derived prostate cancer xenografts (PDXs) are demanding to establish. METHODS Sixty-seven patients who were undergoing palliative transurethral surgery or radical prostatectomy for histologically confirmed, clinically relevant prostate cancer were included in the study. Fresh prostate cancer tissue was identified by frozen analysis in 48 patients. The cancer tissue was transplanted subcutaneously and under the renal capsule of NSG and NOG mice supplemented with human testosterone. All growing PDXs were evaluated by histology and immunohistochemistry. RESULTS Early assessment of the animals at least three months after transplantation included 27/48 (56.3%) eligible PDX cohorts. PDX growth was detected in 10/27 (37%) mouse cohorts. Eight of the ten PDXs were identified as human donor derived lymphomas, including seven Epstein Barr virus (EBV)-positive diffuse large B-cell lymphomas and one EBV-negative peripheral T-cell lymphoma. One sample consisted of benign prostatic tissue, and one sample comprised a benign epithelial cyst. Prostate cancer was not detected in any of the samples. CONCLUSIONS Tumors that arise within the first three months after prostate cancer xenografting may represent patient-derived EBV-positive lymphomas in up to 80% of the early growing PDXs when using triple knockout NSG immunocompromised mice. Therefore, lymphoma should be excluded in prostate cancer xenografts that do not resemble typical prostatic adenocarcinoma. Prostate 9999: XX-XX, 2014. © 2015 Wiley Periodicals, Inc.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Urologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Urologie

UniBE Contributor:

Thalmann, George; Cecchini, Marco Giovanni and Rentsch, Cyrill Achim

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0270-4137

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Katharina Morgenegg

Date Deposited:

26 Feb 2015 13:33

Last Modified:

26 Jun 2016 01:58

Publisher DOI:

10.1002/pros.22939

PubMed ID:

25585936

Uncontrolled Keywords:

prostate cancer, xenograft, lymphoma, triple knock out

BORIS DOI:

10.7892/boris.63402

URI:

https://boris.unibe.ch/id/eprint/63402

Actions (login required)

Edit item Edit item
Provide Feedback